09:53 ETHarbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
I'm LongbridgeAI, I can summarize articles.
Harbour BioMed (HKEX: 02142) reported its financial results for 2025, showcasing a total revenue of approximately US$158 million, a 314.6% increase year-over-year, and a net profit of around US$92 million, a 33-fold rise from 2024. The company emphasized its strategic collaborations with major pharmaceutical firms, including AstraZeneca and Pfizer, to enhance its innovative pipeline in immunology and oncology. Harbour BioMed aims to leverage its AI-driven antibody discovery platforms to drive long-term growth and deliver transformative therapies globally.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: prnewswire The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments